

Letter

## Extraarticular Manifestations and Comorbidities in Patients With Rheumatoid Arthritis

*To the Editor:*

We read with great interest the article by Gunderson et al, which reported the multimorbidity burden in rheumatoid arthritis (RA).<sup>1</sup> We appreciate that the authors estimated comorbidities in RA with a novel perspective, thus giving us a chance to further clarify the RA patient complexity. We would like, however, to discuss some key points.


First, in this article,<sup>1</sup> rheumatic disease (ie, RA) and its extra-articular manifestations (eg, interstitial lung disease, secondary Sjögren syndrome, vasculitis) were not included as comorbidities. We suggest that the authors take Felty syndrome (FS) into account<sup>2</sup> because FS is characterized by the triad of seropositive RA with destructive joint involvement, splenomegaly, and neutropenia. Additionally, normocytic and normochromic anemia are also kinds of FS complications. As deficiency anemia was considered one of the comorbidities discussed in this article, differentiating it from anemias caused by FS can make the analysis clearer.

Second, we suggest that the authors include osteoporosis as one of the comorbidities.<sup>3</sup> The glucocorticoid medications often prescribed for the treatment of RA have the possibility of triggering bone loss.<sup>4</sup> Moreover, the pain and loss of joint function caused by RA can result in inactivity, further putting patients with RA at risk of osteoporosis.

Third, we recommend collecting the drinking status of patients, if possible. There have been many studies focused on the link between alcohol intake and RA in recent years. Some studies considered moderate drinking as a preventing factor for developing RA,<sup>5</sup> while others quantified the hepatotoxic risk of alcohol consumption in patients with RA.<sup>6</sup> Adding information on the drinking status of patients can make the association between RA and multimorbidity more thoroughly understood.<sup>7</sup>

Pei-Yu Liao<sup>1</sup> , Medical student

Shin-Liang Liao<sup>2</sup> , MD

Yung-Po Liaw<sup>3</sup> , PhD

<sup>1</sup>School of Medicine, Chung Shan Medical University, Taichung City;

<sup>2</sup>Department of Emergency Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City;

<sup>3</sup>Department of Public Health and Institute of Public Health, and Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung City, Taiwan.

PYL and SLL contributed equally to this article.

The authors declare no conflicts of interest relevant to this article.

Address correspondence to Dr. Y.P. Liaw, Department of Public Health and Institute of Public Health, Chung Shan Medical University, and Department of Medical Imaging, Chung Shan Medical University Hospital, No. 110, Sec. 1, Jianguo N. Rd., South District, Taichung City 40201, Taiwan. Email: liawyp@csmu.edu.tw.

## REFERENCES

1. Gunderson TM, Myasoedova E, Davis JM 3rd, Crowson CS. Multimorbidity burden in rheumatoid arthritis: a population-based cohort study. *J Rheumatol* 2021;48:1648-54.
2. Sayah A, English JC 3rd. Rheumatoid arthritis: a review of the cutaneous manifestations. *J Am Acad Dermatol* 2005;53:191-209.
3. Dequeker J, Geusens P. Osteoporosis and arthritis. *Ann Rheum Dis* 1990;49:276-80.
4. Hanly JG, Lethbridge L. Use of disease-modifying antirheumatic drugs, biologics, and corticosteroids in older patients with rheumatoid arthritis over 20 years. *J Rheumatol* 2021;48:977-84.
5. Jin Z, Xiang C, Cai Q, Wei X, He J. Alcohol consumption as a preventive factor for developing rheumatoid arthritis: a dose-response meta-analysis of prospective studies. *Ann Rheum Dis* 2014;73:1962-7.
6. Humphreys JH, Warner A, Costello R, Lunt M, Verstappen SMM, Dixon WG. Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. *Ann Rheum Dis* 2017;76:1509-14.
7. Meer E, Thrastardottir T, Wang X, et al. Risk factors for diagnosis of psoriatic arthritis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis: a set of parallel case-control studies. *J Rheumatol* 2022;49:53-9.